Evaxion Biotech A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVAX research report →
Range $9 – $10
Price Chart
About the company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers.
- CEO
- Helen Katrina Tayton-Martin
- IPO
- 2021
- Employees
- 46
- HQ
- Horsholm, ND, DK
Get TickerSpark's AI analysis on EVAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.21M
- P/E
- -0.45
- Fwd P/E
- 75.00
- PEG
- 0.00
- P/S
- 2.34
- P/B
- 0.12
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -115.98%
- Net Margin
- -115.49%
- ROE
- -61.39%
- ROIC
- -46.68%
Latest fiscal year · YoY change
- Revenue
- $7.53M+125.1%
- Gross Profit
- $7.53M+125.1%
- Op Income
- $-9,234,000
- Net Income
- $-7,707,000+27.1%
- EPS
- $-1.21+87.7%
- OCF Growth
- +48.6%
- FCF Growth
- +48.6%
- 52W High
- $6.92
- 52W Low
- $2.03
- 50D MA
- $3.07
- 200D MA
- $3.43
- Beta
- 0.27
- RSI (14)
- 35
- Avg Volume
- 91.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evaxion used Q3 to pivot hard toward oncology, highlighted by strong EVX-01 melanoma data and a runway extension toward the end of 2027.· November 19, 2026
- Management is refocusing all internal resources on immuno-oncology and will progress only oncology assets in-house.
- EVX-01 showed continued clinical and immune-response validation in advanced melanoma, including 89% precision in predicting immunogenic neoantigens.
- The company plans to advance off-the-shelf programs EVX-04 (AML) and EVX-05 (GBM) toward the clinic, while seeking partnerships for broader EVX-01 use.
- Cash runway was extended toward the end of 2027 through ATM usage and disciplined spending.
- Infectious disease and autoimmune programs are not being abandoned, but are being pushed toward partnering or early proof-of-concept work rather than internal priority status.
Evaxion reported no recognized revenue in Q3, versus revenue last year from the out-licensing of EVX-B3 to Merck/MSD. Net loss for the quarter was $3.5 million, compared with $4.6 million profit in the same quarter last year. The cash position at the end of September was $13.3 million, including $2.2 million from ATM proceeds received in August 2026; the company also received another $800,000 from the ATM in October, not reflected in quarter-end cash. Management said the yearly cash burn rate is still expected to be approximately $14 million, and it remains on track for the full year to deliver according to financial plan. Forward, the company expects cash runway toward the end of 2027 and said the EVX-04 clinical trial application remains on track to be filed by the end of the year (and later referenced as expected in the second half of this year).
Helen Tayton-Martin said the company is concentrating on where it sees the most external validation and value creation: oncology, especially through AI-Immunology. She pointed to Moderna’s phase III melanoma data and Evaxion’s own EVX-01 results as supporting the pivot, and said the platform can support both personalized and off-the-shelf cancer vaccines across multiple indications. Her tone was confident but pragmatic, emphasizing partnerships for areas outside the new core focus and saying the company wants to maximize value with the resources it has.
Thomas Schmidt said the quarter reflected a more normalized financial profile, with no recognized revenue, lower operating costs in R&D and G&A, and more spend directed to business development. He reiterated an unchanged expected yearly cash burn of about $14 million and said the company has extended its runway toward the end of 2027 through ATM usage and disciplined resource allocation. He also noted $13.3 million in cash at September quarter-end, $2.2 million of ATM proceeds received in August, another $800,000 received in October, equity of $8.1 million, and the 2025 debt cancellation of $4.1 million tied to the European Investment Bank arrangement, with warrants that could bring up to another $1.5 million if exercised.
Analysts focused on why the company is pivoting away from infectious disease, and management said the driver is not lack of belief in those assets but stronger momentum and value in oncology. Questions also centered on EVX-01 expansion, and management said partners are mainly interested in the existing advanced melanoma validation, the quality of antigen predictions, turnaround time, and whether the platform can move into other indications and antigen types. On autoimmune disease, management said work is still at an early proof-of-concept stage, with tolerogenic vaccine and autoantibody-binder concepts being readied for lab testing rather than a defined IND-ready product. The company also said EVX-04 data will be presented at ASH in December and more trial-design details should come with the CTA filing later this year.
The call gave investors a clear strategic focus: Evaxion is concentrating on oncology where it sees the strongest validation and partner interest. Management highlighted EVX-01’s advanced melanoma data, an 89% target-precision rate, and sustained T-cell responses, while also pointing to a path for both off-the-shelf and personalized programs. The balance sheet runway improvement to the end of 2027 also reduces near-term financing pressure.
The quarter had no recognized revenue, and the company remains dependent on future partnering, clinical execution, and potential CTA progress to create value. Management acknowledged that the CD8-to-clinical-response question is not yet answered by the current dataset, and EVX-04 still has not reached CTA filing. Infectious disease and autoimmune efforts are being deprioritized internally, which could delay or limit value realization if oncology programs do not translate into partnerships or clinical wins.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.8%
- Shares Outstanding
- 6.32M
- Float Shares
- 5.10M
of shares held by institutions
19 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Merck & Co., Inc. | 1.21M | 0 |
| Ikarian Capital, LLC | 74.70K | 0 |
| Renaissance Technologies LLC | 46.20K | ▲ 12.40K |
| Rathbones Group PLC | 45.72K | 0 |
| Citadel Advisors LLC | 36.58K | ▲ 18.81K |
| Annis Gardner Whiting Capital Advisors, LLC | 30.00K | 0 |
| J. Safra Sarasin Holding AG | 22.90K | 0 |
| Jane Street Group, LLC | 21.70K | ▲ 1.12K |
| Rhumbline Advisers | 19.97K | ▼ 1.88K |
| Boothbay Fund Management, LLC | 18.43K | 0 |
| Smartharvest Portfolios, LLC | 17.96K | ▲ 4.50K |
| Stonepine Capital Management, LLC | 16.57K | ▼ 996 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Bitsch-Norhave Jens | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Mar 18, 26 | Mattsson Andreas Holm | other | 0 |
| Jan 31, 25 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 0 |
| Dec 21, 23 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 22 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 24 | Mattsson Andreas Holm | other | 0 |
| Jan 1, 23 | Mattsson Andreas Holm | other | 0 |
| Mar 18, 26 | Soegaard Marianne | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVAX coverage
Recent articles, reports, and earnings notes.
No research on EVAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVAX report →Evaxion A/S (EVAX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 19
Evaxion announces strategy and business update and third quarter 2026 financial results
globenewswire.com · Nov 19
Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026
globenewswire.com · Nov 18
Evaxion announce 2027 financial calendar
globenewswire.com · Nov 12
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
globenewswire.com · Nov 9
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
globenewswire.com · Nov 6
Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis
defenseworld.net · Nov 6
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.